Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2025-12-26 @ 12:28 AM
Study NCT ID:
NCT05120960
Status:
WITHDRAWN
Last Update Posted:
2024-04-17
First Post:
2021-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-12
Completion Date Type:
ACTUAL
First Submit Date:
2021-11-03
First Submit QC Date:
None
Study First Post Date:
2021-11-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-15
Last Update Post Date:
2024-04-17
Last Update Post Date Type:
ACTUAL